Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumours: rationale and efficacy.

Conclusions: IMA+PI3Ki has significant anti-tumour efficacy in GIST xenografts as compared to single agent treatment, resulting in more prominent tumour volume reduction and enhanced induction of apoptosis. Categorization of GIST based on KIT genotype and PI3K/PTEN genomic status combined with dose optimization is suggested for patient selection for clinical trials exploring such combinations. PMID: 25316817 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25316817?dopt=Abstract

Source: Clinical Cancer Research - October 14, 2014 Category: Cancer & Oncology Authors: Van Looy T, Wozniak A, Floris G, Sciot R, Li H, Wellens J, Ulla V, Fletcher JA, Manley PW, Debiec-Rychter M, Schoffski P Tags: Clin Cancer Res Source Type: research